Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Operating Officer

Chief Financial Officer

President and CEO

Chief Development Officer

Chief Scientific Officer

See Remarks

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious me...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-01	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-13	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-03-13	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-03-04	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-03-04	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-12-27	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2023-12-27	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2023-12-14	Premium	sold	Premium	Premium	Premium	President and CEO
2023-12-11	Premium	sold	Premium	Premium	Premium	President and CEO
2023-12-11	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-12-08	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2023-12-08	Premium	acquired	Premium	Premium	Premium	President and CEO

AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for AKRO